Oxford halts trial of AstraZeneca COVID vaccine in children and teenagers over blood-clotting issue

Published Apr 06 2021 at 5:37 PM GMT
  • The University of Oxford has paused administering doses of the COVID-19 vaccine it developed with AstraZeneca PLC in a small UK study aimed at evaluating its safety and effectiveness in children and teenagers, to wait for further information on rare blood-clotting issues that have been found in a small group of adults that received it, the Wall Street Journal reported Tuesday.
  • The trial was started in mid-February and involves more than 200 young people aged 6 to 17 years old, the paper said.
  • It cited an Oxford spokesman as saying that the trial had not found any safety issues, but that broader concerns and a review of the vaccine by regulators in the UK and European Unions were behind the move.
  • The European Medicines Agency said earlier it expects to update the public on its investigation of the blood-clotting issue later this week.
  • Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move.


  • Published Apr 6, 2021 5:37 PM GMT